IART
NASDAQIntegra LifeSciences Holdings Corporation
SectorHealth CareIndustryMedical/Dental Instruments
News · 26 weeks56+333%
2026-04-192026-10-11
Mix2090d
- Other8(40%)
- SEC Filings5(25%)
- Earnings3(15%)
- Insider3(15%)
- Analyst1(5%)
Latest news
25 items- PRIntegra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual MeetingPRINCETON, N.J., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a global leader in medical technology, today announced its participation in the 2026 American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO, taking place October 17-20 in Los Angeles, California. At this year's meeting, Integra will showcase its growing portfolio of ENT technologies and instruments, including the ACCLARENT AERA® Eustachian Tube Treatment, TruDi® Navigation System, MicroFrance® ENT and Laparoscopy Instruments, Bien-Air® Drill and Shaver Systems and RELIEVA SPINPLUS® Balloon Sinuplasty System. Additionally, Integra is
- PRINTEGRA LIFESCIENCES HOLDINGS CORPORATION IART INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 21.2% Share DropThe law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IART) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE FIRM’S INVESTIGATION]What Happened?On October 2, 2026, Integra released its third quarter 2026 financial results, revealing a quarterly revenue of $410 million to $412 million, below consensus estimates of $416.3 million. Additionally, the Company lowered its full-year 2026 revenue guidance to $1.634 billion to $1.654 billion from $1.654 b
- INSIDERSEC Form 3 filed by Integra LifeSciences Holdings Corporation3 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- SECSEC Form 8-K filed by Integra LifeSciences Holdings Corporation8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
- PRIntegra Announces Pricing of Senior Secured NotesPRINCETON, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) (the "Company") today announced the pricing of $450,000,000 aggregate principal amount of 9.500% senior secured notes due 2033 (the "Notes"). The Notes will be general senior secured obligations of the Company and will be guaranteed by the Company’s wholly-owned domestic subsidiaries that are guarantors under the Company’s senior secured credit facilities. The sale of the Notes is expected to close on or about October 19, 2026, subject to customary closing conditions. The Company intends to use the net proceeds from the offering of Notes, together with borrowings under new credit fac
- PRIntegra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026PRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release third quarter 2026 financial results on Wednesday, October 21, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of t
- PRNasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the WeekVANCOUVER, BC, Oct. 3, 2026 /CNW/ -- Stock Preachers News Commentary - Big technology names pulled the Nasdaq Composite to a weekly gain while the Dow Jones Industrial Average and Russell 2000 closed the week in the red, underscoring a narrow rally as the quarter turned over. The S&P 500 slipped from its prior week's close despite a strong Friday session. Volatility eased, with the VIX down on the day, while crude oil fell sharply and the 10-year Treasury yield ticked higher. Several companies issued contracts, guidance updates, and acquisition news during the stretch. Active Companies from around the markets with current developments this week include: RTX (NYSE:RTX), Integra LifeSciences H
- SECIntegra LifeSciences Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
- PRIntegra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 GuidancePRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026 guidance. "Our third quarter results were impacted by the July flooding event at our Cincinnati facility," said Stuart Essig, Chairman and Chief Executive Officer. "Our teams have made significant progress executing recovery plans and supporting customers. As we have gained additional visibility into the recovery timeline and production ramp, we now have a clearer understanding of the expected impact on our third quarter results and full
- PRIntegra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan BPRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced the launch of a proposed $600 million seven-year Senior Secured Term Loan B as part of a broader refinancing transaction. The Company intends to use the net proceeds from the Term Loan B, together with other sources of financing, to refinance certain of its existing indebtedness and pay associated fees and expenses. "This transaction allows us to refinance our existing debt, extend maturities and maintain financial flexibility. It positions us well as we continue to focus on disciplined capital allocation and deleveraging
- PRIntegra LifeSciences Announces 100th Patient Enrolled in AERA® Pediatric RegistryPRINCETON, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences (NASDAQ:IART), a leading global medical technology company, announced today the enrollment of the 100th patient in the AERA® Pediatric Registry, a prospective, multicenter observational registry evaluating the real-world clinical performance of the Acclarent AERA Eustachian Tube Balloon Dilation System in pediatric patients eight or older. The milestone represents one-third of the registry’s planned enrollment of 300 patients and reflects the continued collaboration of participating investigators, research coordinators and clinical sites across the United States. Launched in July 2025, the registry is designed to gen
- INSIDERNew insider Shinn Lesha R claimed ownership of 26,838 shares (SEC Form 3)3 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- PRIntegra LifeSciences Marks 20 Years of CUSA® Technology with Liver Surgery Education at ACS Clinical Congress 2026PRINCETON, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences (NASDAQ:IART) will mark 20 years of CUSA® technology within its portfolio at the American College of Surgeons (ACS) Clinical Congress 2026, taking place September 26-29 in Washington, D.C. The company will feature surgeon-led educational programming focused on liver surgery, including presentations and clinical discussions featuring the CUSA Clarity Ultrasonic Surgical Aspirator System and MicroFrance® laparoscopic surgical instrumentation. As part of ACS’s Innovation Theater programming, Integra LifeSciences will feature presentations from internationally recognized liver surgeons to share clinical perspectives and
- SECIntegra LifeSciences Holdings Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
- PRIntegra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare ConferencePRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that Lea Knight, chief financial officer, and Michael McBreen, chief commercial officer, will present at the 2026 Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 2:15 p.m. ET. Stuart Essig, chairman and chief executive officer, will present at the 2026 Morgan Stanley Healthcare Conference on Tuesday, September 15, 2026, at 4:05 p.m. ET. A live webcast of the presentations will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS. About Integra LifeSciences
- INSIDEREVP & CHRO Veillon-Berteloot Chantal covered exercise/tax liability with 1,455 shares, decreasing direct ownership by 7% to 20,772 units (SEC Form 4)4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- SECSEC Form 10-Q filed by Integra LifeSciences Holdings Corporation10-Q - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
- SECIntegra LifeSciences Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
- PRIntegra LifeSciences Reports Second Quarter 2026 Financial ResultsPRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2026. Second Quarter 2026 Highlights Second quarter revenues of $418.8 million increased 0.8% on a reported basis and 0.7% on an organic basis compared to the prior year. Second quarter GAAP earnings per diluted share of $0.06, compared to $(6.31) in the prior year. Adjusted earnings per diluted share of $0.56, compared to $0.45 in the prior year.The Company is updating its reported revenue guidance range to $1.654 billion to $1.695 billion to reflect the impact of a
- ANALYSTUBS initiated coverage on Integra with a new price targetUBS initiated coverage of Integra with a rating of Neutral and set a new price target of $19.00
- PRIntegra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release second quarter 2026 financial results on Wednesday, July 29, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the
- ANALYSTBMO Capital Markets initiated coverage on Integra with a new price targetBMO Capital Markets initiated coverage of Integra with a rating of Market Perform and set a new price target of $19.00
- PROne Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical AestheticsIssued on behalf of Conexeu Sciences Inc.Conexeu Sciences Inc. (NASDAQ:CNXU) completed the 12-month P.R.O.O.F phase of its CXU preclinical program, which met its objectives across three pillars, facial, body, and mechanical performance, as it advances a single-formulation regenerative platform toward a predicate-based 510(k).USA News Group News CommentaryRENO, Nev. , July 9, 2026 /CNW/ -- In regenerative medicine, the durable advantage rarely comes from a single product; it comes from a platform that can be pointed at more than one problem. That is the framing behind a milestone from Conexeu Sciences Inc. (NASDAQ:CNXU), a preclinical-stage regenerative tissue company that has completed the P
- INSIDERSVP, Fin & Princ Acct Officer Mosebrook Jeffrey covered exercise/tax liability with 937 shares, decreasing direct ownership by 3% to 34,516 units (SEC Form 4)4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
- INSIDERSEC Form 4 filed by EVP & President, SS Singh Harvinder4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
IART FAQ
6 questionsWhat does Integra LifeSciences Holdings Corporation do?
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps...Where does IART stock trade?
Integra LifeSciences Holdings Corporation (IART) is listed on NASDAQ.What sector and industry is IART in?
Integra LifeSciences Holdings Corporation operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about IART?
Integra LifeSciences Holdings Corporation has had 8 recent analyst actions on file. The most recent action was from UBS: Neutral with a $1900.00 price target on 2026-07-28. Recent price targets range from $1600.00 to $2500.00.What companies are similar to IART?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare IART side-by-side with any of them on Quantisnow.How can I track IART on Quantisnow?
Quantisnow aggregates Integra LifeSciences Holdings Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IART to receive live email and push alerts on every new disclosure.